Detailed explanation of the applicable population and therapeutic effects of neratinib/neratinib

Neratinib is an oral targeted therapy drug that has occupied an important position in the field of breast cancer treatment. In particular, it has a significant effect on the treatment ofHER2-positive breast cancer. HER2-positive breast cancer, which accounts for approximately 15-20% of all breast cancer cases, is caused by uncontrolled growth of cells caused by abnormalities in the HER2 gene. Neratinib effectively curbs the proliferation and spread of cancer cells by precisely inhibiting the HER2 signaling pathway. So, which patients are suitable for neratinib?

For HER2-positive patients who have undergone breast cancer surgery, radiotherapy or systemic therapy, neratinib can be used as a powerful weapon in adjuvant therapy. After these treatments, neratinib helps reduce the risk of cancer recurrence and improves patients' survival and quality of life. For patients with early-stage HER2-positive breast cancer, neratinib also shows its therapeutic potential. As part of a single-agent treatment regimen, it can provide patients with long-term adjuvant therapy after trastuzumab-based adjuvant therapy to further consolidate the therapeutic effect.

In addition, the combination of neratinib and capecitabine has become an effective treatment strategy for patients with advanced or metastatic HER2-positive breast cancer. This combination therapy is suitable for patients who have received two or more anti-HER2 regimens. The addition of neratinib not only helps control the progression of tumors, but also prolongs the survival of patients to a certain extent.

Not all breast cancer patients are candidates for neratinib. When doctors decide whether to use neratinib treatment, they will comprehensively consider the patient's age, condition, previous treatment response and other factors. At the same time, because neratinib may cause side effects such as nausea, vomiting, diarrhea, fatigue, etc., patients need to maintain close communication with their doctors during the treatment process and report any uncomfortable reactions in a timely manner to ensure the safety and effectiveness of the treatment.